Objective:To investigate the effects of Gongliuxiao Capsule on inflammatory factors, tumor markers, sex hormones and vascular endothelial function in patients with uterine fibroids. Methods:130 patients with uterine f...Objective:To investigate the effects of Gongliuxiao Capsule on inflammatory factors, tumor markers, sex hormones and vascular endothelial function in patients with uterine fibroids. Methods:130 patients with uterine fibroids admitted to our hospital from October 2015 to March 2017 were enrolled. According to the treatment, they were divided into single treatment group and combined medication group, with 65 cases in each group. The changes of inflammatory factors, tumor markers, sex hormones and vascular endothelial function were compared before and after treatment in the two groups.Results: There were no significant differences in the levels of sex hormones, inflammatory factors, tumor markers and vascular endothelial function between the two groups (P>0.05). The levels of sex hormones E2, P, FSH and LH, the levels of inflammatory factors TNF-α, MMP-9 and IGF-1, tumor markers CA125, CA19-9 and vascular endothelial function VEGF and b-FGF were significantly lower in the two groups (P<0.05). The levels of E2, P, FSH and LH in the combined drug groupswere (154.12±16.20) pmol/L, (9.12±1.02) μg/L, (13.84±1.42) U/L and (12.77±1.36) U/L, respectively,which were significantly lower than the single drug group level (P<0.05). The levels of CA125 and CA19-9 in the combined drug group were (27.89±2.88) U/mL and (28.09±3.04) U/mL, respectively, which were significantly lower than the single drug group (P<0.05). The levels of TNF-α, MMP-9 and IGF-1 in the combined drug group were (24.16±2.63) ng/L, (159.22±16.82) μg/L and (69.75±7.09) μg/L, respectively, which were significantly lower than the single drug group(P<0.05). The levels of VEGF and b-FGF in the combination group were (138.29±14.32) μg/L and (98.59±10.02) μg/L, respectively, which were significantly lower than the single drug group (P<0.05).Conclusion:Mifepristone combined with Gongliuxiao Capsule can alleviate endocrine disorders, relieve inflammatory stress response and improve vascular endothelial function in patients with uterine fibroids. It is展开更多
目的:探讨宫瘤消胶囊联合血府逐瘀汤治疗子宫肌瘤的疗效。方法:选取2011年3月至2015年1月期间我院确诊治疗的子宫肌瘤患者98例,依据随机分配原则分为对照组和联合组,每组49例,对照组患者给予血府逐瘀汤(100 m L/次,2次/d)治疗;联合组患...目的:探讨宫瘤消胶囊联合血府逐瘀汤治疗子宫肌瘤的疗效。方法:选取2011年3月至2015年1月期间我院确诊治疗的子宫肌瘤患者98例,依据随机分配原则分为对照组和联合组,每组49例,对照组患者给予血府逐瘀汤(100 m L/次,2次/d)治疗;联合组患者在此基础上给予加服宫瘤消胶囊(口服,3粒/次,3次/d)治疗,2组疗程均为3个月,采用化学发光法检测所有患者治疗前后血清中促卵泡素(FSH)、雌二醇(E_2)、孕酮(P)水平,通过GE彩超采集测量肌瘤矢状径和冠状径线数据,统计分析所有患者治疗前后月经期、月经量和血清激素水平,肌瘤大小测量值变化。结果:联合组和对照组患者治疗有效率分别为91.84%、73.47%,前者明显高于后者,差异有统计学意义(P<0.05);2组患者治疗后月经周期、经血量水平均低于治疗前,差异无统计学意义(P>0.05);联合组患者治疗后肌瘤体积较对照组明显变小,差异有统计学意义(P<0.05);治疗前后血清中FSH、E_2、P水平轻度下降,差异无统计学意义(P>0.05)。结论:宫瘤消胶囊联合血府逐瘀汤治疗子宫肌瘤的疗法具有活血化瘀、理气止痛、缩小瘤体之功效,可有效改善子宫肌瘤引起的月经过多、经期腹部坠胀等临床症状,而对患者激素水平无过多影响,有利于患者生理功能的恢复,值得临床作进一步推广。展开更多
文摘Objective:To investigate the effects of Gongliuxiao Capsule on inflammatory factors, tumor markers, sex hormones and vascular endothelial function in patients with uterine fibroids. Methods:130 patients with uterine fibroids admitted to our hospital from October 2015 to March 2017 were enrolled. According to the treatment, they were divided into single treatment group and combined medication group, with 65 cases in each group. The changes of inflammatory factors, tumor markers, sex hormones and vascular endothelial function were compared before and after treatment in the two groups.Results: There were no significant differences in the levels of sex hormones, inflammatory factors, tumor markers and vascular endothelial function between the two groups (P>0.05). The levels of sex hormones E2, P, FSH and LH, the levels of inflammatory factors TNF-α, MMP-9 and IGF-1, tumor markers CA125, CA19-9 and vascular endothelial function VEGF and b-FGF were significantly lower in the two groups (P<0.05). The levels of E2, P, FSH and LH in the combined drug groupswere (154.12±16.20) pmol/L, (9.12±1.02) μg/L, (13.84±1.42) U/L and (12.77±1.36) U/L, respectively,which were significantly lower than the single drug group level (P<0.05). The levels of CA125 and CA19-9 in the combined drug group were (27.89±2.88) U/mL and (28.09±3.04) U/mL, respectively, which were significantly lower than the single drug group (P<0.05). The levels of TNF-α, MMP-9 and IGF-1 in the combined drug group were (24.16±2.63) ng/L, (159.22±16.82) μg/L and (69.75±7.09) μg/L, respectively, which were significantly lower than the single drug group(P<0.05). The levels of VEGF and b-FGF in the combination group were (138.29±14.32) μg/L and (98.59±10.02) μg/L, respectively, which were significantly lower than the single drug group (P<0.05).Conclusion:Mifepristone combined with Gongliuxiao Capsule can alleviate endocrine disorders, relieve inflammatory stress response and improve vascular endothelial function in patients with uterine fibroids. It is
文摘目的:探讨宫瘤消胶囊联合血府逐瘀汤治疗子宫肌瘤的疗效。方法:选取2011年3月至2015年1月期间我院确诊治疗的子宫肌瘤患者98例,依据随机分配原则分为对照组和联合组,每组49例,对照组患者给予血府逐瘀汤(100 m L/次,2次/d)治疗;联合组患者在此基础上给予加服宫瘤消胶囊(口服,3粒/次,3次/d)治疗,2组疗程均为3个月,采用化学发光法检测所有患者治疗前后血清中促卵泡素(FSH)、雌二醇(E_2)、孕酮(P)水平,通过GE彩超采集测量肌瘤矢状径和冠状径线数据,统计分析所有患者治疗前后月经期、月经量和血清激素水平,肌瘤大小测量值变化。结果:联合组和对照组患者治疗有效率分别为91.84%、73.47%,前者明显高于后者,差异有统计学意义(P<0.05);2组患者治疗后月经周期、经血量水平均低于治疗前,差异无统计学意义(P>0.05);联合组患者治疗后肌瘤体积较对照组明显变小,差异有统计学意义(P<0.05);治疗前后血清中FSH、E_2、P水平轻度下降,差异无统计学意义(P>0.05)。结论:宫瘤消胶囊联合血府逐瘀汤治疗子宫肌瘤的疗法具有活血化瘀、理气止痛、缩小瘤体之功效,可有效改善子宫肌瘤引起的月经过多、经期腹部坠胀等临床症状,而对患者激素水平无过多影响,有利于患者生理功能的恢复,值得临床作进一步推广。
